Literature DB >> 11600563

Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors.

F Savagner1, B Franc, S Guyetant, P Rodien, P Reynier, Y Malthiery.   

Abstract

Oxyphilic tumors (oncocytomas or Hürthle cell tumors) form a rare subgroup of thyroid tumors characterized by cells containing abundant mitochondria. The relationship between the mitochondrial proliferation and the pathogenesis of these tumors is unknown. We have assessed the expression of the mitochondrial ND2 and ND5 (subunits of the nicotinamide adenine dinucleotide dehydrogenase complex) genes and the nuclear UCP2 (uncoupling protein 2) gene in 22 oxyphilic thyroid tumors and matched controls. The consumption of oxygen in mitochondria from tumors was determined by polarography. ATP assays were used to explore the mitochondrial respiratory chain activity and the oxidative phosphorylation coupling in seven fresh thyroid tumors and controls. Adenosine triphosphate synthesis was significantly lower in all the tumors, compared with controls, suggesting that a coupling defect in oxidative phosphorylation may be a cause of mitochondrial hyperplasia in oxyphilic thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600563     DOI: 10.1210/jcem.86.10.7894

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Mitochondria and cancer.

Authors:  Valdemar Máximo; Jorge Lima; Paula Soares; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2009-04-03       Impact factor: 4.064

Review 2.  NO control of mitochondrial function in normal and transformed cells.

Authors:  Celia H Tengan; Carlos T Moraes
Journal:  Biochim Biophys Acta Bioenerg       Date:  2017-02-16       Impact factor: 3.991

3.  Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines.

Authors:  Eleonore Fröhlich; Inge Fink; Richard Wahl
Journal:  Invest New Drugs       Date:  2008-09-20       Impact factor: 3.850

4.  Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors.

Authors:  Valdemar Máximo; Paula Soares; Jorge Lima; José Cameselle-Teijeiro; Manuel Sobrinho-Simões
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

5.  Oxyphilic and non-oxyphilic thyroid carcinoma cell lines differ in expressing apoptosis-related genes.

Authors:  E Allìa; P Cassoni; T Marrocco; M Volante; B Bussolati; M Wong; O H Clark; M Papotti
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

6.  Genipin-induced inhibition of uncoupling protein-2 sensitizes drug-resistant cancer cells to cytotoxic agents.

Authors:  Ryan J Mailloux; Cyril Nii-Klu Adjeitey; Mary-Ellen Harper
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

7.  Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies.

Authors:  Elena Bonora; Giovanni Tallini; Giovanni Romeo
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

Review 8.  Relevance of mitochondrial genetics and metabolism in cancer development.

Authors:  Giuseppe Gasparre; Anna Maria Porcelli; Giorgio Lenaz; Giovanni Romeo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

9.  PGC-1-related coactivator modulates mitochondrial-nuclear crosstalk through endogenous nitric oxide in a cellular model of oncocytic thyroid tumours.

Authors:  Mahatsangy Raharijaona; Soazig Le Pennec; Julie Poirier; Delphine Mirebeau-Prunier; Clothilde Rouxel; Caroline Jacques; Jean-Fred Fontaine; Yves Malthiery; Rémi Houlgatte; Frédérique Savagner
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

10.  Death-associated protein 3 is overexpressed in human thyroid oncocytic tumours.

Authors:  C Jacques; J-F Fontaine; B Franc; D Mirebeau-Prunier; S Triau; F Savagner; Y Malthiery
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.